The Fabhalta iptacopan FDA approval announced by Novartis on July 17, 2026, gives adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression the first complement inhibitor cleared to significantly slow kidney function decline. The US Food and Drug Administration granted traditional approval to Fabhalta (iptacopan) under a priority review designation, converting the accelerated approval the drug first received in August 2024 for reducing proteinuria in primary IgAN into a full, standard approval based on two-year outcomes data.
Novartis positioned this Fabhalta iptacopan FDA approval as a milestone built on data from the Phase III APPLAUSE-IgAN study, which tracked kidney function using estimated glomerular filtration rate (eGFR) over 24 months. Patients on Fabhalta showed an annualized mean change from baseline in eGFR of -3.0 mL/min/1.73 m²/yr, compared with -5.7 mL/min/1.73 m²/yr for placebo, translating into a 48 percent slower rate of kidney function decline. Clinically meaningful reductions in urine protein were observed as early as two weeks into treatment and were sustained throughout the study period.
Disease Burden Driving the Fabhalta Iptacopan FDA Approval
Roughly 25 people per million are newly diagnosed with IgAN worldwide each year, making it one of the most common autoimmune kidney diseases globally. Up to 50 percent of IgAN patients with persistent proteinuria go on to progress to kidney failure within 10 to 20 years of diagnosis, frequently requiring dialysis or a kidney transplant. That trajectory has left patients and caregivers searching for therapies that intervene earlier in the disease course rather than managing end-stage complications after the fact.
The APPLAUSE-IgAN study also characterized Fabhalta’s safety profile as favorable and consistent with data reported previously. The most common adverse events among patients with IgAN taking Fabhalta were abdominal pain, dizziness, and nausea. Because Fabhalta can increase the risk of serious infections caused by encapsulated bacteria, it is available only through a Risk Evaluation and Mitigation Strategy (REMS) program that requires appropriate vaccinations before treatment begins.
Trial Data Behind the Fabhalta Iptacopan FDA Approval
The consistency of Fabhalta’s performance across key kidney outcomes in APPLAUSE-IgAN, summarized in the data table below, formed the clinical basis the FDA relied on when converting the accelerated approval into a traditional one. Novartis said Fabhalta outperformed placebo across these endpoints throughout the two-year study. Because those results held up over 24 continuous months rather than a shorter interim window, they gave the FDA the durability evidence needed to move this Fabhalta iptacopan FDA approval from an accelerated to a traditional status.
Today’s approval reinforces Fabhalta’s role in preserving kidney function by significantly slowing disease progression, an outcome that matters deeply to patients at risk of long-term kidney damage,
Victor Bultó, President, US, Novartis
Mechanism of Action Behind the Fabhalta Iptacopan FDA Approval
Fabhalta (iptacopan) is an oral Factor B inhibitor designed to selectively target the alternative complement pathway, one of the key drivers of glomerular inflammation and kidney damage in IgAN. By inhibiting Factor B, Fabhalta is designed to reduce ongoing complement-mediated injury and slow disease progression rather than simply treating downstream symptoms. The drug has now received regulatory approvals across multiple complement-mediated diseases beyond IgAN and continues to be evaluated in a range of rare kidney conditions.
Novartis is building out a broader IgAN portfolio alongside Fabhalta, which includes Vanrafia (atrasentan) and the investigational compound zigakibart, giving physicians multiple mechanisms of action to choose from as they individualize treatment for patients whose disease courses vary widely. Novartis said it is also working to keep the therapy accessible, noting that nearly 100 percent of US patients pay $10 or less per month for Fabhalta through its support programs. That affordability commitment sits alongside the Fabhalta iptacopan FDA approval as part of the company’s broader push to get mechanism-targeted IgAN treatment to patients sooner rather than later.
Novartis frames the approval within a longer-term commitment to kidney health that it traces back more than 40 years to its early work in transplant medicine. The company says kidney conditions have historically drawn less funding and research attention than other therapeutic areas, leaving a treatment landscape weighted toward reactive, end-stage disease management. Its stated goal going forward is to target the underlying causes of kidney disease so that dialysis and transplantation can be delayed or avoided altogether.
APPLAUSE-IgAN Trial – Key Efficacy Results
| Endpoint | Fabhalta (iptacopan) | Placebo | Result |
|---|---|---|---|
| Annualized eGFR change (baseline, 2-yr) | -3.0 mL/min/1.73 m²/yr | -5.7 mL/min/1.73 m²/yr | 48% slower decline |
| Proteinuria reduction onset | As early as 2 weeks | — | Sustained through treatment period |
| Trial phase / design | Phase III, APPLAUSE-IgAN | — | 2-year outcomes data |
Safety Profile Summary
| Category | Detail |
|---|---|
| Most common adverse events | Abdominal pain, dizziness, nausea |
| Key safety warning | Increased risk of serious infections from encapsulated bacteria |
| Risk mitigation | REMS program; vaccination required prior to treatment |
| Overall profile | Favorable, consistent with prior reported data |
Regulatory Timeline
| Date | Milestone |
|---|---|
| August 2024 | FDA accelerated approval for proteinuria reduction in primary IgAN |
| July 17, 2026 | FDA traditional approval for slowing kidney function decline (priority review) |
